2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2916 Raas inhibition with losartan reduces extracellular volume fraction in sickle cell anemia: A pilot cardiac MRI study

Omar Niss, MD, Sassan Hashemi, MD2, Cara Morin, MD3, MacKenzie Tasset4, Zhenqi Zhu, PhD5, Punam Malik, MD6, Charles T Quinn, MD, MS7
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Background
Diffuse myocardial fibrosis is a key feature of the cardiomyopathy of sickle cell anemia (SCA) and can be quantified longitudinally using cardiac MRI (CMR)-derived extracellular volume (ECV). In untreated patients, ECV remains stable over 2 years, with only minimal annual change (mean -1.1%, SD 2.7%) [Niss et al. Blood RCI, 2025], providing a stable reference against which an antifibrotic therapeutic effect can be tested. We have previously demonstrated that targeting the renin-angiotensin-aldosterone system (RAAS) in SCA mouse model reduces myocardial fibrosis. However, the mechanisms and treatment of myocardial fibrosis in humans with SCA remain unknown.

Methods
This was a pilot, prospective, open-label study of losartan for 12 months in patients with HbSS [NCT05012631] aimed to evaluate the effect of RAAS inhibition in sickle cell cardiomyopathy. Participants underwent CMR and echocardiography before and after losartan, along with laboratory and biomarker testing reflecting fibrosis and collagen turnover (PICP, galectin-3, CTGF), myocardial stress (NTproBNP, sST2), inflammation (IL-18), and renal/hypoxic stress (NGAL), measured at baseline, during, and at end of study. Given the small sample size, correlations between biomarkers and ECV are reported by coefficient magnitude and direction rather than by significance testing, as p-values for correlations are unreliable at this n.

Results
Seven participants completed the study (mean±SD age 16.7 ± 8.5 years, range 6-30; 3M/4F). Baseline hemoglobin was 8.7 ± 0.5 g/dL; absolute reticulocyte count was 0.33 ± 0.25 x106/mcL. All participants had elevated ECV at baseline, consistent with prior studies (mean 33.2 ± 2.3%). All patients tolerated escalation to full-dose losartan without hypotension or hyperkalemia, and all completed the study procedures and tolerated losartan.

At end of study, ECV decreased to 30.8 ± 3.2% (Δ -2.4 ± 3%, P = 0.039 for change from zero), indicating a reduction in diffuse myocardial fibrosis. This decline exceeded the mean annual change previously reported in an untreated historical cohort (Δ -1.1 ± 2.7%).

At baseline, ECV showed the strongest associations with degree of anemia (r = −0.77) and sST2 (r = 0.65); there were weaker associations with CTGF (r = 0.46) and PICP (r = 0.39).

After 12 months of losartan, sST2 and NGAL decreased significantly (53%, ratio 0.47, 95% CI 0.42–0.53, P = 0.0003; and 17%, ratio 0.83, 95% CI 0.70–0.98, P = 0.03, respectively), while PICP showed a trend toward decline (29%, ratio 0.71, 95% CI 0.47–1.08, P = 0.08) and IL-18 increased (40%, ratio 1.40, 95% CI 1.12–1.75, P = 0.01). Changes in NT-proBNP, galectin-3, and CTGF were not individually significant; however, per-patient changes in both galectin-3 and CTGF correlated with changes in ECV (r = 0.82, P = 0.03, and r = 0.79, P = 0.048, respectively)

Among echocardiographic diastolic parameters, there were trends in a favorable direction, with the largest changes seen in left atrial volume index (-3 ± 4.7 ml/m2), lateral e′ (+2.6 ± 5.3 ms), and lateral E/e′ ratio (-0.6 ± 1.7).

Hemoglobin was unchanged (8.7 ± 0.5 to 8.7 ± 1.6 g/dL). Change in hemoglobin showed the strongest negative associations with change in IL-18 (r = -0.68) and change in galectin-3 (r = -0.54).

Conclusion
This pilot study suggests a role for RAAS inhibition in myocardial fibrosis in humans with SCA. ECV decreased beyond what is seen in untreated patients. Notably, collagen turnover (PICP), sST2, and NGAL declined despite persistent anemia and rising IL-18, an inflammatory marker implicated in sickle cardiomyopathy. Because sST2 more closely reflects myocardial fibrotic remodeling than hemodynamic loading (unlike NT-proBNP), its reduction further supports a RAAS-mediated antifibrotic effect that may act independently of hemodynamic (anemia-related) and inflammatory pathways. Fibrosis biomarkers tracked with ECV changes in this small sample, alongside a favorable signal in diastolic function. These findings support a mechanistic and potential therapeutic role for RAAS targeting in sickle cell cardiomyopathy that warrants evaluation in adequately powered studies.

Omar Niss, MD: Pfizer - Ended employment in the past 24 months; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Vertex - Consultancy (Includes expert testimony)